Technical Analysis for BWAY - Brainsway Ltd.

Grade Last Price % Change Price Change
D 5.38 -0.37% -0.02
BWAY closed down 0.37 percent on Friday, May 17, 2024, on 54 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It ran into resistance at its 50 day moving average.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
20 DMA Support Bullish 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
50 DMA Resistance Bearish -0.37%
Down 3 Days in a Row Weakness -0.37%
50 DMA Resistance Bearish -0.74%

   Recent Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Brainsway is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), for which Brainsway received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 (for MDD) and in August 2018 (for OCD). Brainsway is currently conducting clinical trials of Deep TMS in other psychiatric, neurological and addiction disorders, including smoking cessation and post-traumatic stress disorder, and is planning trials for opioid addiction, fatigue in multiple sclerosis (MS) and post-stroke rehabilitation.
Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Neuroscience FDA Mental Health Opioids Stroke Multiple Sclerosis Psychiatry Major Depressive Disorder Neuromodulation Neurophysiology Depressive Disorder Smoking Neurotechnology Neuropsychology Post Traumatic Stress Disorder Smoking Cessation Treatment Of Major Depressive Disorder Obsessive Compulsive Disorder Addiction Neuromodulation Products Treatment Of Depression Non Invasive Neuromodulation Products

Is BWAY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.615
52 Week Low 1.49
Average Volume 71,345
200-Day Moving Average 5.06
50-Day Moving Average 5.46
20-Day Moving Average 5.36
10-Day Moving Average 5.55
Average True Range 0.31
RSI (14) 48.72
ADX 14.29
+DI 23.46
-DI 18.52
Chandelier Exit (Long, 3 ATRs) 5.25
Chandelier Exit (Short, 3 ATRs) 5.54
Upper Bollinger Bands 6.10
Lower Bollinger Band 4.62
Percent B (%b) 0.51
BandWidth 27.55
MACD Line 0.02
MACD Signal Line 0.02
MACD Histogram -0.0005
Fundamentals Value
Market Cap 89.42 Million
Num Shares 16.6 Million
EPS -0.48
Price-to-Earnings (P/E) Ratio -11.21
Price-to-Sales 3.45
Price-to-Book 2.44
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.61
Resistance 3 (R3) 5.62 5.56 5.57
Resistance 2 (R2) 5.56 5.50 5.55 5.55
Resistance 1 (R1) 5.47 5.47 5.44 5.46 5.54
Pivot Point 5.41 5.41 5.40 5.40 5.41
Support 1 (S1) 5.32 5.35 5.29 5.31 5.22
Support 2 (S2) 5.26 5.32 5.25 5.21
Support 3 (S3) 5.17 5.26 5.19
Support 4 (S4) 5.16